Logout Login Cart iconShop
Contact Sales

Search

Filters

Content Type

Products

Clear Filters

Search Results for "500k fc points price Buyfc26coins.com is FC 26 coins official site..uOKm"

Looking for quality documents?
external link icon
Repligen to Present at the William Blair 2018 Growth Stock Conference
WALTHAM, Mass., May 30, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Tony J. Hunt, Chief Executive Officer, will present at the William Blair 2018 Growth Stock Conference. The conference will take place on June 12-14 in Chicago, and the Repligen presentation is scheduled for Wednesday, June 13 at 11:20 a.m. CT.

A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time following the live event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein
external link icon
Repligen to Present at Jefferies 2018 Global Healthcare Conference
WALTHAM, Mass., May 23, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a global bioprocessing company focused on the development and commercialization of highly innovative technologies to improve biopharmaceutical manufacturing processes, today announced that Jon K. Snodgres, Chief Financial Officer, will present at the Jefferies 2018 Global Healthcare Conference. The conference will take place on June 5-8 in New York City, and the Repligen presentation is scheduled for Wednesday, June 6 at 3:00 p.m. EDT. A live webcast of the presentation will be accessible through the Investor Relations section of Repligen’s website, and will be archived for a period of time following the live event.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein
external link icon
Repligen to Participate in 15th Annual Craig-Hallum Institutional Investor Conference
WALTHAM, Mass., May 17, 2018 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading life sciences company focused on bioprocessing technology leadership, today announced that Jon K. Snodgres, Chief Financial Officer, will participate in the 15 th Annual Craig-Hallum Institutional Investor Conference, being held on May 30 th in Minneapolis.

The conference is a series of one-on-one meetings with investors and does not include a formal presentation. An updated investor presentation can be accessed on the event date by visiting the Investor Relations section of the Repligen Corporation website at  www.repligen.com.

About Repligen Corporation
Repligen Corporation (NASDAQ:RGEN) is a global bioprocessing company that develops and commercializes highly innovative products that deliver cost and process efficiencies to biological drug manufacturers worldwide. Our portfolio includes Protein products (Protein A affinity ligands, cell culture growth
external link icon
Repligen to Present at Jefferies’ 2017 Global Annual Healthcare Conference
WALTHAM, Mass., May 31, 2017 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that management will present at Jefferies’ 2017 Global Annual Healthcare Conference, to be held June 6-9, 2017 in New York.  The Repligen presentation is scheduled for Wednesday, June 7 at 10:30 a.m.
A live webcast of the presentation will be accessible through the Investor Events section of the Company’s website, and will be available for replay for a limited period of time following the conference event. About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to improve the biological drug manufacturing process. Our portfolio includes Protein products (Protein A affinity ligands, cell culture growth factors), Chromatography products (OPUS® pre-packed columns, chromatography
external link icon
Repligen to Participate in Stephens Inc. Fall Investment Conference 2016
WALTHAM, Mass., Nov. 07, 2016 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a leading innovator and provider of high-value products to improve the process of manufacturing biologic drugs, today announced that it will participate in Stephens’ Fall Investment Conference, being held November 8-9, 2016 in New York. Repligen President and CEO Tony J. Hunt, and CFO Jon Snodgres, will deliver a roundtable presentation on Tuesday, November 8 at 11:00 a.m.  Repligen’s current investor presentation is accessible through the Investor Events section of the Company’s website. About Repligen Corporation Repligen Corporation (NASDAQ:RGEN) is a bioprocessing company focused on the development, manufacture and commercialization of highly innovative products used to manufacture biologic drugs. Our bioprocessing products are sold to major life sciences companies, biopharmaceutical development companies and contract manufacturing organizations worldwide. We are the leading manufacturer of
external link icon
Repligen to Present at Stifel Nicolaus Healthcare Conference 2012
- Thursday, September 6, 10:20 a.m. EDT - Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will be presenting at the upcoming Stifel Nicolaus Healthcare Conference in Boston. Dr. Herlihy will provide a corporate update and discuss the Company’s recent decision to focus corporate strategy on the growth of its bioprocessing business. The Repligen presentation is scheduled for Thursday, September 6, 2012 at 10:20 a.m. EDT. A live webcast and subsequent archived replay of the presentation will be available through the Investors section of Repligen’s corporate website at www.repligen.com . To access the live webcast, please log on through the Company’s website approximately 15 minutes prior to the presentation. About Repligen Corporation Repligen Corporation is a life sciences company focused on the development, production and commercialization of products used in the process of manufacturing biological drugs. Our
external link icon
Repligen Corporation to Present at William Blair Growth Conference
WALTHAM, Mass., May 22, 2025 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that it will be participating at the William Blair 45 th Annual Growth Stock Conference being held June 3 – 5 in Chicago. Olivier Loeillot, President and Chief Executive Officer is scheduled to present a company overview on June 3 rd at 1:20 p.m. CT. A live webcast of the conference presentation will be accessible through Repligen’s Investor Relations website at www.repligen.com , and will be available for replay for a limited period of time following the event. About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that enable efficiencies in the process of manufacturing biological drugs. We are “inspiring advances in bioprocessing” for the customers we serve; primarily biopharmaceutical drug
external link icon
Repligen to Present at the 38th Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 07, 2020 (GLOBE NEWSWIRE) - Repligen Corporation (NASDAQ:RGEN), a life sciences company focused on bioprocessing technology leadership, today announced that the Company will present at the 38 th annual J.P. Morgan Healthcare Conference, to be held at the Westin St. Francis in San Francisco. Tony J. Hunt, Repligen’s president and chief executive officer, is scheduled to present a company overview on Wednesday, January 15, 2020 at 11:30 a.m. PT.

A live audio webcast of the presentation will be accessible through the Investor Events section of the Company’s website at www.repligen.com . A recorded replay will be available approximately one hour after the conclusion of the live event, and will be accessible for up to 90 days following the event.

About Repligen Corporation
Repligen Corporation is a global life sciences company that develops and commercializes highly innovative bioprocessing technologies and systems that increase
external link icon
Repligen to Present at 2015 Leerink Global Healthcare Conference
WALTHAM, Mass., Feb. 4, 2015 (GLOBE NEWSWIRE) - Repligen Corporation (Nasdaq:RGEN) today announced that the Company will present at the 2015 Leerink Global Healthcare Conference to be held February 11-12 at the Waldorf Astoria hotel in New York. Management is scheduled to participate in an analyst-moderated "fireside chat" with investors at 2:40 p.m. EST on Thursday, February 12, 2015. A live audio webcast of this discussion will be accessible through the Investor Events section of Company's website. A replay of the webcast will also be accessible for a period of time following the event. About Repligen Corporation Repligen Corporation (Nasdaq:RGEN) is a life sciences company focused on the development and commercialization of high-value consumable products used in the process of manufacturing biological drugs. Our bioprocessing products are sold to major life sciences and biopharmaceutical companies worldwide. We are the leading manufacturer of Protein A affinity ligands, a critical
external link icon
Repligen to Present at JMP Securities Healthcare Conference 2012
Repligen Corporation (NASDAQ:RGEN) today announced that Walter C. Herlihy, Ph.D., President and Chief Executive Officer, will present a corporate update at the JMP Securities Healthcare Conference 2012 in New York. The Repligen presentation is scheduled for Friday, July 13, at 11:00 a.m. EDT. A live webcast and subsequent archived replay of the presentation will be available through the Investors section of Repligen’s corporate website at www.repligen.com . To access the live webcast, please log on through the Company’s website approximately 15 minutes prior to the presentation. About Repligen Corporation
Repligen Corporation is a leading supplier of critical biologic products used to manufacture biologic drugs. Repligen also applies its expertise in biologic product development to RG1068, a synthetic hormone being developed as a novel imaging agent for the diagnosis of a variety of pancreatic diseases. In addition, the Company has two central nervous system (CNS) rare disease
Close modal

A new look. A better way to explore Repligen.

We’ve redesigned Repligen.com to help you find the right solutions faster, with greater clarity and less effort.

Find what you need faster
Get to the right information with quicker site speed

Explore the site with ease
Navigate easily with an intuitive, simple site structure

Access product details instantly
Find products and resources faster, in fewer clicks

Get support when you need it
Connect with our team when you need support